Surrozen said despite SZN-043 demonstrating changes in liver function assays, there was not enough clinical benefit for ...

Surrozen is discontinuing its sole clinical-stage candidate and pivoting to its preclinical ophthalmology pipeline after the ...

Hepatitis C drug Ganovo won a top clinical research award due to its successful performance in a phase 3 trial. The prestigious industry award was granted at the 15th Infectious Disease National ...

Less than three years after Sovaldi’s launch, hepatitis C (hep C) treatment has been transformed, thanks to the drug and rapidly-evolving competition in the field. But only a small percentage of ...

Researchers assessed epidemiologic trends of incident hepatitis C virus infection among patients with HIV infection engaged in care in the US.

Surrozen is dropping its sole clinical asset after the drug failed at Phase I ... is being discontinued in severe alcohol-associated hepatitis. The therapy was under evaluation in two Phase ...